Paclitaxel-loaded lipid nanoparticles for topical application: the influence of oil content on lipid dynamic behavior, stability, and drug skin penetration
Source abstract
Abstract
Paclitaxel (PAC) has shown potential for regulating hyperkeratosis in skin diseases and its encapsulation in lipid nanoparticles could improve topical treatments. So, solid lipid nanoparticles (SLN) and nanostructured lipid carriers with 12.5 % (NLC1) and 25 % (NLC2) oil content were obtained and characterized. Lipid dynamic behavior was investigated through electron paramagnetic resonance spectroscopy (EPR) and comparative evaluations of EPR, and stability and skin permeation studies were performed. High entrapment efficiency was obtained for all formulations (over 90 %). The absence (SLN) or addition of 12.5 % oil (NLC1) did not significantly alter nanoparticle mean diameter, but 25 % oil (NLC2) produced smaller particles (270.6 ± 13.5 nm). EPR studies showed that 12.5 % oil increased NLC1 fluidity at the surface. Surprisingly, more oil increased NLC2 superficial rigidity, due to the decrease in nanoparticle mean diameter and additional PAC accumulation in the superficial environment. The oil in lipid matrices improved the physicochemical stability of NLC formulations, and drug-oil chemical affinity prevented PAC expulsion during storage time. NLC2 improved PAC skin penetration and was the only formulation capable of enhancing PAC penetration to deeper skin layers (about 6.48 ± 1.39 µg/cm2). PAC-NLC2 seemed to be very promising nanocarriers for the topical delivery of PAC.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Amjadi I, Rabiee M, Hosseini MS, Mozafari M (2012) Synthesis and characterization of doxorubicin-loaded poly (lactide-co-glycolide) nanoparticles as sustained-release anticancer drug delivery system. Appl Biochem Biotechnol 168:1434–144710.1007/s12010-012-9868-4 ↗
2. Andrade LM, Reis CF, Maione-Silva L, Anjos JLV, Alonso A, Serpa RC, Marreto RN, Lima EM, Taveira SF (2014) Impact of lipid dynamic behavior on physical stability, in vitro release and skin permeation of genistein-loaded lipid nanoparticles. Eur J Pharm Biopharm. doi: 10.1016/j.ejpb.2014.04.015
3. Budil DE, Lee S, Saxena S, Freed JH (1996) Nonlinear-least-square analysis of slow-motion EPR spectra in one and two dimensions using a modified Levenberg-Marquardt algorithm. J Megn Reson A 120:155–18910.1006/jmra.1996.0113 ↗
4. Contreras MJF, Soriano MMJ, Diéguez AR (2005) In vitro percutaneous absorption of all-trans retinoic acid applied in free form or encapsulated in stratum corneum lipid liposomes. Int J Pharm 297:134–14510.1016/j.ijpharm.2005.03.018 ↗
5. Das S, Ng WK, Tan RBH (2012) Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 47:139–15110.1016/j.ejps.2012.05.010 ↗
6. Fang JY, Fang CL, Liu CH, Su YH (2008) Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 70:633–64010.1016/j.ejpb.2008.05.008 ↗
7. FDA, Food and Drug Administration—Guidance for Industry (2001) Analytical procedures and methods validation: chemistry, manufacturing and controls documentation. Rockville: US Food and Drug Administration 33
8. Haag SF, Chen M, Peters D, Keck CM, Taskoparan B, Fahr A, Teuloff C, Bittl R, Lademann J, Schäfer-Korting M, Meinke MC (2011) Nanostructured lipid carriers as nitroxide depot system measured by electron paramagnetic resonance spectroscopy. Int J Pharm 421:364–36910.1016/j.ijpharm.2011.10.009 ↗
9. Huang ZR, Hua SC, Yang YL, Fang JY (2008) Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers and lipid emulsion. Acta Pharmacol Sin 29:1094–110210.1111/j.1745-7254.2008.00829.x ↗
10. Jenning V, Thünemann AF, Gohla SH (2000) Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167–17710.1016/S0378-5173(00)00378-1 ↗
11. Jin C, Yang Z, Yang J, Li H, He Y, An J, Bai L, Dou K (2014) Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a target therapy for liver cancers stem cells. J Nanopart Res 16:1–15
12. Jores K, Mehnert W, Mäder K (2003) Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm Res 20:1274–128310.1023/A:1025065418309 ↗
13. Kilfoyle BE, Sheihet L, Zhang Z, Laohoo M, Kohn J, Michniak-Kohn BB (2012) Development of paclitaxel-tyrospheres for topical skin treatment. J Control Release 163:18–2410.1016/j.jconrel.2012.06.021 ↗
14. Knox SN, Robinson JB, Im DD, Logan L, Rosenshein NB (2000) The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus. Gynecol Oncol 76:118–12210.1006/gyno.1999.5590 ↗
15. Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM (2011) Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effect on size, physical stability and particle matrix structure. Int J Pharm 406:163–17210.1016/j.ijpharm.2010.12.036 ↗
16. Lippacher A, Müller RH, Mäder K (2001) Preparation of semi-solid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 124:9–1210.1016/S0378-5173(00)00623-2 ↗
17. Lopez RFV, Seto JE, Blankschtein D, Langer DR (2011) Enhancing the transdermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate. Biomaterials 32:933–94110.1016/j.biomaterials.2010.09.060 ↗
18. Maione-Silva L, Rocha KADR, Oliveira LC, Taveira SF, Lima EM (2012) Development and validation of a simple and rapid lipid chromatography method for the determination of genistein in skin permeation studies. Biol Pharm Bull 35:1986–199010.1248/bpb.b12-00442 ↗
19. Mendanha SA, Moura SS, Anjos JLV, Valadares MC, Alonso A (2013) Toxicity of terpenes on fibroblast cells compared to their hemolytic potential and increase in erythrocyte membrane fluidity. Toxicol In Vitro 27:323–32910.1016/j.tiv.2012.08.022 ↗
20. Michniak BB, Player MR, Chapman JM Jr, Sowell JW Sr (1994) Azone analogues as penetration enhancers: effect of different vehicles on hydrocortisone acetate skin permeation and retention. J Control Release 32:147–15410.1016/0168-3659(94)90053-1 ↗
21. Müller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131–S15510.1016/S0169-409X(02)00118-7 ↗
22. Müller RH, Petersen RD, Hommoss A, Pardeike J (2007) Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–53010.1016/j.addr.2007.04.012 ↗
23. Paolino D, Celia C, Trapasso E, Cilurzo F, Fresta M (2012) Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm 81:102–11210.1016/j.ejpb.2012.02.008 ↗
24. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EMT, Yoong C, Robertson TA, Soyer HP, Roberts MS (2011) Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 63:470–49110.1016/j.addr.2011.01.012 ↗
25. Puglia C, Blasi P, Rizza L, Schoubben A, Boninca F, Rossi C, Ricci M (2008) Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 357:295–30410.1016/j.ijpharm.2008.01.045 ↗
26. Schneider DJ, Freed JH (1989) Spin labeling. Theory and applications. Berliner LJ, Reuben J (eds), Biological magnetic resonance, plenum, Press, New York
27. Souza LG, Silva EJ, Martins ALL, Mota MF, Braga RC, Lima EM, Valadares MC, Taveira SF, Marreto RN (2011) Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 79:189–19610.1016/j.ejpb.2011.02.012 ↗
28. Taveira SF, Nomizo A, Lopez RFV (2009) Effect of the iontophoresis of a chitosan gel on doxorubicin skin penetration and cytotoxicity. J Control Release 134:35–4010.1016/j.jconrel.2008.11.002 ↗
29. Taveira SF, Araújo LM, De Santana DC, Nomizo A, De Freitas LA, Lopez RFV (2012) Development of cationic solid lipid nanoparticles with factorial design-based studies for topical administration of doxorubicin. J Biomed Nanotechnol 8:219–22810.1166/jbn.2012.1383 ↗
30. Vitorino C, Almeida A, Sousa J, Lamarche I, Gobin P, Marchand S, Couet W, Oliveri JC, Pais A (2014) Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies. Eur J Pharm Biopharm 86:133–14410.1016/j.ejpb.2013.12.004 ↗
31. Williams AC, Barry BW (2004) Penetration enhancers. Adv Drug Deliv Rev 56:603–61810.1016/j.addr.2003.10.025 ↗
32. Win KY, Feng SS (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713–272210.1016/j.biomaterials.2004.07.050 ↗
33. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–127210.1016/j.addr.2003.12.002 ↗
34. Yang Y, Corona A, Schubert B, Reeder R, Henson MA (2014) The effect of oil type on the aggregation stability of nanostructured lipid carriers. J Colloid Interface Sci 418:261–27210.1016/j.jcis.2013.12.024 ↗